Epidermolysis bullosa

Displaying 1 study

  • A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa Rochester, MN

    The primary objective of this study is to determine whether administration of FCX-007 in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Recessive Dystrophic Epidermolysis Bullosa (RDEB) and confirmed mutation of the type VII collagen gene (COL7A1) gene.

.

Mayo Clinic Footer